September 15th. University of Washington Awarded Life Sciences Discovery Fund (LSDF) Funding to Advance Novel Artemisinin Technologies for Cancer Treatment in Collaboration with Artemisia BioMedical, Inc. The University of Washington is one of six Washington life science organizations to be awarded funding from the state's Life Sciences Discovery Fund (LSDF). In collaboration with Artemisia BioMedical, Inc, a research team under the leadership of Tomikazu Sasaki, PhD, will receive approximately $1.5 million over three years to advance development of novel artemisinin compounds for cancer treatment.
November 26th. Dr Tomikazu Sasaki Interview and Podcast on Genetic Engineering & Biotechnology News. Dr Tomikazu Sasaki is interviewed by Genetic Engineering & Biotechnology News regarding his recent publication on novel targeted artemisinin compounds.
October 4th. Report on Synthesis and Anti-Cancer Activity of Novel Targeted Artemisinin Compounds. In the October, 2008 online issue of Cancer Letters, University of Washington researchers reported on the synthesis and anti-cancer activity of novel targeted artemisinin compounds.
January 31st. Malaria-Infected Mice are Cured by Oral Administration of New Artemisinin Derivatives. Johns Hopkins researchers have cured malaria-infected mice with only three low oral doses of a new series of potent, long lasting synthetic artemisinin dimers.
July 24th. Artemisia BioMedical Awarded Washington Technology Center Research Funding. Artemisia BioMedical, Inc. is one of five companies awarded Washington State funding for innovative commercial technology applications developed in partnership with Washington researchers.
May 14th. Artemisia BioMedical Signs Exclusive Option Agreement with Johns Hopkins University to Novel Artemisinin Dimers. Artemisia BioMedical, Inc. has signed an Exclusive Option License Agreement with The Johns Hopkins University (Baltimore, MD) to a portfolio of novel artemisinin trioxane dimers.
May 7th. Artemisia BioMedical Signs Exclusive Option Agreement with University of Alabama at Birmingham to Novel Transferrin Receptor-Binding Peptides. Artemisia BioMedical, Inc. has signed an Exclusive Option License Agreement with the University of Alabama at Birmingham (Birmingham, AL) to a portfolio of novel peptides, which bind to the human transferrin receptor.
December 1st. Case Report of a Pituitary Macroadenoma Treated with Artemether. In the December, 2006 issue of Integrative Cancer Therapies (Vol. 5, No. 4, 391-94), Narendra Singh of the University of Washington Department of Bioengineering and Vijay Kumar Panwar of the Primary Health Center in Jaroda, India, reported on the case of a patient with pituitary macroadenoma treated with the artemisinin analog artemether.
June 7th. Artemisia BioMedical Signs Exclusive Option Agreement with University of Washington to Artemisinin Technologies. Artemisia BioMedical, Inc. has signed an Exclusive Option License Agreement with the University of Washington (Seattle, WA) to a portfolio of novel artemisinin-based technologies.